Zhifei pushes buyback and new vaccine pipeline despite losses
Share buyback signals confidence Zhifei plans to buy back 150-300 million yuan of its own shares, at up to 18.22 yuan each, for staff incentives. Buybacks shrink the number of shares and show management thinks the stock is cheap, which supports the price.
The buyback is a direct capital action aimed at supporting the share price.
Three new vaccine candidates enter trials Its units won Chinese regulator acceptance or approval to test a nasal spray RSV vaccine, a freeze-dried rabies vaccine and a recombinant rotavirus vaccine. These add future products, but the company says they won't affect near-term results.
Pipeline progress is the main new operating news and supports long-term growth expectations.
Semaglutide injection registration accepted Zhifei's controlling subsidiary had its production registration application for semaglutide injection accepted by the drug regulator. This moves the company beyond vaccines into a fast-growing weight-loss and diabetes market, though approval and sales are still uncertain.
It is a new regulatory step that broadens the product story beyond vaccines.
First-quarter loss shows weak core business The company reported first-quarter 2026 revenue of 2.15 billion yuan and a net loss of 388 million yuan. That loss is the real counterweight: buybacks and pipeline news don't fix current weak earnings, so the stock's rise rests on future hopes.
It gives the fair counterweight that current profits are still negative.